Studie
MetroBiotech, Co-Founded by Harvard's David Sinclair, Launches Human Trial of New NAD+ Booster MIB-725
PRIMÄR
Tier 4
2023
StudiedesignPRIMÄR
TierTier 4, Animal or preclinical only
År2023
Tidskriftnmn.com
N7
Tillagd i NO1GEVITYaug 3, 2026
Citerad av
1 encyklopediartiklar refererar till denna studie.